Alvotech Suffers Delay On Higher-Strength Adalimumab In US

Facility Inspection Obstacles Lead FDA To Defer Action On Humira Biosimilar

 
• By David Wallace
  
Delay Blocks Black White
Alvotech’s biosimilar has suffered a setback due to inspection delays • Source: Alamy

More from Biosimilars

More from Products